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Introduction
Enterococcus is the third most common cause of infective endocarditis (IE), accounting for 10% of episodes. 1 Standard therapy for enterococcal endocarditis requires the combination of either ampicillin or vancomycin with gentamicin or streptomycin. 2, 3 Clinical failures, antimicrobial resistance and nephrotoxicity have led to the search for new therapeutic options such as ampicillin/ ceftriaxone, daptomycin or linezolid. 2, 3 Daptomycin is registered for the treatment of right-sided endocarditis caused by Staphylococcus aureus. We report our experience with daptomycin in the treatment of enterococcal IE and compare it with the results of standard therapy in our institution.
Patients and methods

Design
A retrospective descriptive study that evaluates the effectiveness of daptomycin compared with conventional antibiotic regimens in the treatment of enterococcal IE.
Setting
Tertiary teaching hospital (1550 -1750 beds) with a major heart surgery department.
Data records
All patients diagnosed with enterococcal IE from January 2007 to December 2011 were selected. Episodes of IE were identified prospectively by a multidisciplinary team (Group for the Management of Infective Endocarditis of the Gregorio Marañ ó n Hospital; GAME). The hospital's review board and ethics committee approved the study. All patients included gave their informed consent.
Inclusion and exclusion criteria
We included all patients ≥18 years old with a definite or possible Enterococcus faecalis or Enterococcus faecium IE according to the modified Duke criteria, 4 treated with effective antimicrobial therapy for ≥48 h.
'Daptomycin-treated patients' were defined as the patients with enterococcal IE who received ≥7 days of daptomycin within the first 14 days after the diagnostic positive blood culture with a dosage ≥6 mg/kg/day intravenously. We excluded patients who started daptomycin after ≥14 days of other antibiotic regimens and patients with polymicrobial IE defined by the simultaneous isolation of microorganisms other than Enterococcus in blood, heart valve or prosthetic material. 'Ampicillin/ceftriaxone-treated patients' were the patients with enterococcal IE treated with ampicillin (2 g every 6 h) plus ceftriaxone (2 g every 12 h). 'Conventionally treated patients' were patients with enterococcal IE treated with ampicillin (2 g every 6 h) or vancomycin (1 g every 12 h)+gentamicin (1 mg/kg every 8 h).
Microbiological protocol
At least three sets of aerobic and anaerobic blood cultures were performed for patients with suspected IE. Blood was cultured with the BACTEC 9240 system (Becton-Dickinson, Sparks, MD, USA) and bottles were incubated at 378C for a maximum of 20 days. Identification and susceptibility testing for the bacteria isolated were performed with MicroScan panels (Siemens Healthcare Diagnostic, West Sacramento, CA, USA) and conventional microbiological procedures according to CLSI recommendations. 5 Daptomycin MICs were determined using Microscan panel positive combo type 38 and then confirmed by Etest.
Definitions
'Days of bacteraemia' were the days from the first to the last positive blood culture. 'Complications' included embolization, intracardiac abscess, increase in the size of vegetation, cardiac heart failure, CNS event, mycotic aneurysm and persistent bacteraemia. Patients were monitored throughout the duration of antibiotic treatment.
Statistical analysis
Continuous variables were compared using Student's t-test for normally distributed variables and the Mann -Whitney U-test for non-normally distributed variables. The x 2 test or Fisher's exact test was used to compare categorical variables. All tests of significance were two-tailed. Differences were considered to be significant for P values ,0.05. The analysis was carried out with SPSS 17.0, Chicago, IL, USA.
Results
During the 5 year study period, E. faecalis/E. faecium accounted for 15.2% (39/256) of IE episodes. Seven cases were excluded: three with polymicrobial IE and four patients that started daptomycin after ≥14 days of other antibiotic regimen. Of the 32 patients included in the study, 6 were daptomycin-treated patients, 21 were ampicillin/ceftriaxone-treated patients and 5 were conventionally treated patients. There was no statistically significant difference between groups regarding baseline clinical characteristics (Table 1) .
Of the six daptomycin-treated patients, one patient with E. faecium IE resistant to ampicillin and aminoglycosides received daptomycin from the beginning (initial compassionate use). The remaining five had received a median of 8 days (range: 4-13 days) of another initial therapy ( Table 2 ). The indications for daptomycin were outpatient parenteral therapy (2) and b-lactam allergy (3), two of them also with renal failure. None of the patients received daptomycin due to previous treatment failure. All strains were susceptible to daptomycin (MICs ranged from 1 to 2 mg/L) and the mean administered dose was 8.5 mg/kg/day intravenously (range: 6-10 mg/kg/day).
Daptomycin-treated patients had a longer duration of bacteraemia [median 6 (range 1 -13) days versus 1 (range 1 -6) day in ampicillin/ceftriaxone-treated patients and 1 (range 1 -3) day in conventionally treated patients, P, 0.01]. More complications were also observed in the daptomycin-treated group [five (83.3%) versus three (14.3%) in the ampicillin/ceftriaxone-treated group and one (20%) in the conventionally treated group, P, 0.01]. Finally, daptomycin-treated patients more frequently needed an antibiotic regimen change [four (66.7%) versus none (0%) in the ampicillin/ceftriaxone-treated group and one (20%) in the conventionally treated group, P,0.01].
The switch of therapy in the conventionally treated group was due to renal failure secondary to the use of gentamicin. This patient was changed to ceftriaxone/ampicillin. However, the four antimicrobial switches in the daptomycin group were due to treatment failures: two persistent bacteraemias and two clinical worsening (recurrence of fever .388C) with echocardiographic deterioration (new intracardiac abscess and/or increase of vegetation size). These four patients were changed to ampicillin/ ceftriaxone, in two of them after desensitization to b-lactams.
Ampicillin/ceftriaxone-treated patients needed less cardiovascular surgery than daptomycin-treated patients and conventionally treated patients [four (19%) versus three (50%) and four (80%), P¼0.02], without a significant difference between the last two groups. There were no differences regarding adverse events related to antimicrobial therapy [0% versus 0% and one (20%), P¼0.06], median duration of hospital stay after initiation of effective antimicrobial therapy [43 (range 14-77) days versus 32 (range 13 -71) days and 45 (range 35 -48) days, P ¼ 0.83] or mortality [one (16.7%) versus nine (42.9%) and two (49%), P¼0.5] between the daptomycin-treated group, the ampicillin/ceftriaxone-treated group and the conventionally treated group, respectively.
Discussion
We observed that patients with enterococcal endocarditis treated with daptomycin had a higher rate of complications and a longer duration of bacteraemia than patients treated with other Ceró n et al.
regimens. This finding was also reported by Gallagher et al.,
6 who reported bacteraemia .7 days in 30% of patients treated with daptomycin.
The response of S. aureus left-sided endocarditis to daptomycin seems to be similar to that with standard treatment. In contrast, the delayed response observed with Enterococcus could be caused by a 'relative tolerance' of Enterococcus strains to daptomycin that could account for bacterial survival and regrowth after antibiotic removal. 7 It is known that, in general, enterococci are less susceptible in vitro to daptomycin than S. aureus, with a threshold for susceptibility that is four times as high (≤4 versus ≤1 mg/L for S. aureus).
5 Although daptomycin-resistant Enterococcus have been described, 8 all our strains were and remained susceptible according to standard cut-offs.
Another explanation for the poor outcome could be that the recommended doses are too low to treat enterococcal endocarditis. We used an average dose of 8.5 mg/kg/day, which is higher than the officially recommended dose. However, in a recent study with simulated endocardial vegetation infected with vancomycin-resistant Enterococcus (VRE), sustained daptomycin bactericidal activity required the use of 10 -12 mg/kg/day. Clinical information regarding enterococcal bacteraemia treated with daptomycin is scarce. Overall, 39 episodes have been described with a success rate of 52%. 10, 11 Mave et al. 11 reported a retrospective study of 98 adult patients with VRE bacteraemia treated with linezolid or daptomycin. Daptomycin was associated with a trend towards higher mortality (27.7% versus 20.6%), longer duration of bacteraemia (3 versus 2 days) and higher relapse rate (6.7% versus 2.9%), but the differences were not statistically significant.
11
As for endocarditis, three case reports described failures of daptomycin monotherapy.
12 -14 Segreti et al. 15 reported two leftside VRE endocarditis patients treated with daptomycin and aminoglycosides who died. These findings contrast with the results of the US and European Cubicin Outcomes Registry and Experience. 16, 17 Overall, these registries report 36 patients with enterococcal endocarditis with a success rate of 71% and 73%, respectively. However, the majority of the patients had received prior (88%) and/or concomitant anti-Gram-positive therapy (65%). The most common reason for using daptomycin was failure of the previous regimen.
In our opinion, combined therapies need to be investigated further. Favourable results, mainly derived from case reports or animal models, have been reported with daptomycin/gentamicin, daptomycin/tigecycline or a triple combination of daptomycin/ gentamicin/high-dose ampicillin. 12, 18, 19 In vitro studies showed synergy between daptomycin and rifampicin against Enterococcus resistant to both vancomycin and linezolid. 20 Limitations of our study are: (i) the lack of daptomycin serum levels; (ii) the relatively low number of patients; and (iii) a potential indication bias, considering that daptomycin was used as secondline compassionate therapy in five of the six patients. To fully clarify this issue, a larger randomized trial should be conducted.
In our experience, patients who received daptomycin for the treatment of left-sided enterococcal IE presented more complications than patients treated with ampicillin/ceftriaxone or conventional therapy. Accordingly, we warn against the selection of daptomycin as single therapy for the treatment of enterococcal endocarditis. Prospective studies are needed to define its potential role in combination with other drugs.
